Immunovia Publ Revenue vs. Price To Book
| IMMNOV Stock | SEK 0.76 0.09 10.59% |
For Immunovia Publ profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunovia Publ to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunovia publ AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunovia Publ's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunovia publ AB over time as well as its relative position and ranking within its peers.
Immunovia |
Immunovia publ AB Price To Book vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunovia Publ's current stock value. Our valuation model uses many indicators to compare Immunovia Publ value to that of its competitors to determine the firm's financial worth. Immunovia publ AB is considered the number one company in revenue category among its peers. It also is currently regarded as number one stock in price to book category among its peers . The ratio of Revenue to Price To Book for Immunovia publ AB is about 381,245 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunovia Publ by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunovia Publ's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Immunovia Revenue vs. Competition
Immunovia publ AB is considered the number one company in revenue category among its peers. Market size based on revenue of Diagnostics & Research industry is currently estimated at about 874.23 Million. Immunovia Publ adds roughly 844,000 in revenue claiming only tiny portion of equities under Diagnostics & Research industry.
Immunovia Price To Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Immunovia Publ |
| = | 844 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Immunovia Publ |
| = | 2.21 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Immunovia Price To Book Comparison
Immunovia Publ is currently under evaluation in price to book category among its peers.
Immunovia Publ Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunovia Publ, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunovia Publ will eventually generate negative long term returns. The profitability progress is the general direction of Immunovia Publ's change in net profit over the period of time. It can combine multiple indicators of Immunovia Publ, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.
Immunovia Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunovia Publ. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunovia Publ position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunovia Publ's important profitability drivers and their relationship over time.
Use Immunovia Publ in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunovia Publ position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovia Publ will appreciate offsetting losses from the drop in the long position's value.Immunovia Publ Pair Trading
Immunovia publ AB Pair Trading Analysis
The ability to find closely correlated positions to Immunovia Publ could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunovia Publ when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunovia Publ - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunovia publ AB to buy it.
The correlation of Immunovia Publ is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunovia Publ moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunovia publ AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunovia Publ can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunovia Publ position
In addition to having Immunovia Publ in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recycling Thematic Idea Now
Recycling
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Immunovia Stock
To fully project Immunovia Publ's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunovia publ AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunovia Publ's income statement, its balance sheet, and the statement of cash flows.